Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethasone followed by maintenance in primary refractory or relapsed bortezomib naive multiple myeloma patients.

Trial Profile

Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethasone followed by maintenance in primary refractory or relapsed bortezomib naive multiple myeloma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REMMYDYS
  • Most Recent Events

    • 02 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top